Amgen Inc. (AMGN)
| Market Cap | 169.78B |
| Revenue (ttm) | 33.42B |
| Net Income (ttm) | 4.09B |
| Shares Out | 537.20M |
| EPS (ttm) | 7.56 |
| PE Ratio | 41.80 |
| Forward PE | 15.31 |
| Dividend | $9.52 (3.01%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 9,949,726 |
| Open | 311.82 |
| Previous Close | 315.04 |
| Day's Range | 311.18 - 316.30 |
| 52-Week Range | 253.30 - 346.85 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 323.26 (+2.29%) |
| Earnings Date | May 1, 2025 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $323.26, which is an increase of 2.29% from the latest price.
News
Widely used drugs on US imports list from Europe
Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing * Late-Breaking Data to be Presented at AAN 2025 THOUSAND OAKS, Calif. , March 13, 2025 /PRNewswire/ -- Am...
Amgen: Riding The MariTide Of Monthly Weight Loss
Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual mechanism a...
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif. and TOKYO , March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd.
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket
Three of the major pharma companies that I follow have shown a bit of a mixed move in the premarket hours, as the markets try to get a grip on the latest demand for GLP-1 and other medicines.
5 Big Biopharmaceutical Stocks That Are Finding Favor
AbbVie, Gilead Sciences, Amgen, and Johnson & Johnson have held steady amid a fluctuating market.
Trade Tracker: Joe Terranova sells the XBI, buys Amgen
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Amgen Inc. (AMGN) 45th Annual TD Cowen Health Care Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ET Company Participants Jay Bradner - Executive Vice President and Head, R&D Justin Claeys - Vice...
Amgen starts two critical late-stage trials for weight loss drug MariTide
Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a monthly ...
AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
THOUSAND OAKS, Calif. , March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025.
Dogs Of The Dow Chase A "Safer" Buy For March
Verizon is the only Dow Dog meeting the ideal of dividends from $1K invested exceeding its single share price, making it a 'safer' buy. Analysts project net gains of 13.06% to 37.60% from the top ten ...
POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in NEJM and Presented at AAAAI/WAO 2025 THOUSAND OAKS, Calif. , March 1, 2025 /PRNewswire/ -- A...
AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
THOUSAND OAKS, Calif. , Feb. 28, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 45th Annual TD Cowen Health Care Conference at 9:10 a.m.
Trade Tracker: Rob Sechan sells McDonald's and Vertex, buys Texas Pacific Land, Amgen and NRG
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves.
Final Trades: Berkshire Hathaway, Amgen, Prologis and 3M
The Investment Committee give you their top stocks to watch for the second half.
Amgen Stock: Why I Still Rate It A 'Buy'
Amgen Stock: Why I Still Rate It A 'Buy'
10 Undervalued Dividend Growth Stocks: February 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, an...
Amgen plans $200 million investment in India site, CEO says
U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert A. Bradway said at the in...
Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript)
Amgen, Inc. (NASDAQ:AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference Call February 19, 2025 3:00 PM ET Company Participants Jean-Charles Soria - Senior Vice President of R&D Justin Cla...
AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
THOUSAND OAKS, Calif. , Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m.
Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript
Amgen, Inc. (NASDAQ:AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Company Participants Narimon Honarpour - Senior Vice President, Global Develop...
One 'Safer' Buy In 10 February Dogs Of The Dow
Verizon is the only Dow Dog meeting the ideal of dividends from $1K invested exceeding single share price, supported by adequate free cash flow. Analysts project net gains of 15.23% to 33.94% for the ...
AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
THOUSAND OAKS, Calif. , Feb. 7, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m.
23 Upcoming Dividend Increases, Including 2 Kings
Excited to announce dividend hikes for 23 companies, including dividend kings SJW Group and California Water Service Group, with 5% and 7.1% increases. Companies with consistent dividend growth indica...